Repligen (NASDAQ:RGEN) Rating Reiterated by Benchmark

Benchmark reaffirmed their hold rating on shares of Repligen (NASDAQ:RGEN) in a research note published on Monday morning, Benzinga reports.

Several other analysts also recently weighed in on the stock. Guggenheim initiated coverage on shares of Repligen in a research report on Tuesday, June 18th. They set a neutral rating for the company. Stephens reissued an overweight rating and issued a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the stock an overweight rating in a report on Wednesday, July 31st. Royal Bank of Canada reissued an outperform rating and issued a $190.00 target price on shares of Repligen in a report on Wednesday, July 31st. Finally, Deutsche Bank Aktiengesellschaft raised Repligen from a hold rating to a buy rating and decreased their target price for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Repligen currently has an average rating of Moderate Buy and a consensus target price of $189.57.

Repligen Stock Performance

NASDAQ:RGEN opened at $166.79 on Monday. The firm has a market capitalization of $9.34 billion, a PE ratio of 667.19, a price-to-earnings-growth ratio of 5.83 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.24. The business’s fifty day moving average price is $135.35 and its 200 day moving average price is $165.76. Repligen has a 12 month low of $110.45 and a 12 month high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The business had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.53 EPS. On average, sell-side analysts anticipate that Repligen will post 1.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Anthony Hunt sold 20,072 shares of Repligen stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the transaction, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by insiders.

Institutional Trading of Repligen

Several hedge funds have recently modified their holdings of RGEN. YHB Investment Advisors Inc. acquired a new position in Repligen during the first quarter worth $26,000. Andra AP fonden acquired a new position in shares of Repligen during the 2nd quarter worth $25,000. Lazard Asset Management LLC increased its holdings in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 136 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new stake in shares of Repligen in the second quarter valued at about $33,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.